© 2026 MergersCorp M&A International.
is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://dev.cherrycoding.com/mergerscorp/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom
这家待售公司是位于印度班加罗尔的一家医疗保健公司。 公司从事药品和营养补充剂的生产和供应,产品销往全球各地(质量标准符合世界卫生组织–GMP 和 ISO 认证要求)。
公司设备齐全,通过了 ISO 9001 和世界卫生组织 GMP 认证,可满足中美洲、尼日利亚、孟加拉国、柬埔寨、斯里兰卡、马来西亚、多米尼加共和国等国家的订单需求。 该工厂占地面积超过 50000 平方英尺,专门生产片剂、胶囊和口服液。
公司生产非专利产品、营养保健品和草药医疗产品。
财务业绩概要(3 年)
在过去三年中,收入稳步增长,但息税折旧摊销前利润(EBITDA)却有所减少。 息税折旧摊销前利润(EBITDA)减少的原因是,5 年前开始的在线品牌广告支出增加。 这个 D2C 补充剂品牌的任何利润都被投入到品牌营销中,导致整个公司的息税折旧摊销前利润(EBITDA)减少。
产品
438 个非专利药品生产许可证。 其中,公司目前拥有 148 项 CoPP 批准,使我们能够在多个地区国家注册出口产品。
总体竞争优势
小规模生产设施的生产能力高,具有成本优势。 位于班加罗尔市内的生产单位既能获得熟练工人,也能获得非熟练工人。
© 2025 MergersCorp M&A International is a global brand operating through a number of professional firms and constituent entities (“Members”) located throughout the world to provide Investment Banking, Corporate Finance, and Advisory Services and other client-related professional services. The Member Firms (“Members”) are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit our Disclaimer: https://mergerscorp.com/disclaimer. MergersCorp M&A International's franchising program is not offered to individuals or entities located in the United States.
The franchising program is offered by MergersUK Limited, a UK Company with its registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom.
MergersCorp M&A International provides strategic business advisory services, including preparing companies for growth and capital access. Through partnerships with licensed investment bankers, clients can access tailored capital-raising solutions.
U.S. Investment Banking Securities transactions are exclusively conducted by Spektrum Capital Advisors LLC, a Registered Representative of, and Securities Products offered through, BA Securities, LLC, a FINRA-registered broker-dealer. Check the background of investment professionals associated with this site on Broker Check.
This website is operated by MergersUS Inc a US Corporation with registered office at





描述
这家待售公司是位于印度班加罗尔的一家医疗保健公司。 公司从事药品和营养补充剂的生产和供应,产品销往全球各地(质量标准符合世界卫生组织–GMP 和 ISO 认证要求)。
公司设备齐全,通过了 ISO 9001 和世界卫生组织 GMP 认证,可满足中美洲、尼日利亚、孟加拉国、柬埔寨、斯里兰卡、马来西亚、多米尼加共和国等国家的订单需求。 该工厂占地面积超过 50000 平方英尺,专门生产片剂、胶囊和口服液。
公司生产非专利产品、营养保健品和草药医疗产品。
财务业绩概要(3 年)
在过去三年中,收入稳步增长,但息税折旧摊销前利润(EBITDA)却有所减少。 息税折旧摊销前利润(EBITDA)减少的原因是,5 年前开始的在线品牌广告支出增加。 这个 D2C 补充剂品牌的任何利润都被投入到品牌营销中,导致整个公司的息税折旧摊销前利润(EBITDA)减少。
产品
438 个非专利药品生产许可证。 其中,公司目前拥有 148 项 CoPP 批准,使我们能够在多个地区国家注册出口产品。
总体竞争优势
小规模生产设施的生产能力高,具有成本优势。 位于班加罗尔市内的生产单位既能获得熟练工人,也能获得非熟练工人。
Basic Details
Target Price:
$ 12,000,000
Gross Revenue
$1,900,000
EBITDA
TBA
Business ID:
L#20210016
Country
印度
City:
班加罗尔
详情
Similar Businesses
Published on 19 2 月, 2021 在 7:44 下午. 更新 14 3 月, 2026 在 2:12 下午
历史悠久的意大利啤酒品牌和制造业务 – “意大利制造”
€8,500,000
制造业
铝型材制造商
$60,000,000
制造业
金属加工公司
$20,000,000
制造业
面包生产公司
待定
制造业
意大利面制造业务
$2,950,000
制造业
意大利智能电动汽车业务
€2,000,000
制造业
PREVIOUS PROPERTY
拥有 40 年历史的制药企业
NEXT PROPERTY
美国亚利桑那州待售银行